Package Leaflet: Information for the User
Levatik 20 mg film-coated tablets EFG
Vardenafil
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the package leaflet:
This medication contains vardenafil, an active ingredient from the group of medications known as phosphodiesterase 5 inhibitors, which are used to treat erectile dysfunction in adult men, a condition that consists of difficulty in achieving or maintaining an erection.
At least one in ten men has, at some point, problems achieving or maintaining an erection. This can be due to physical or psychological causes, or a combination of both. Regardless of the cause, muscle and blood vessel disorders cause insufficient blood flow to the penis to achieve and maintain an erection.
Vardenafil will only work when you are sexually stimulated. This medication reduces the action of a natural substance in the body that prevents erection. Vardenafil allows you to achieve an erection with sufficient duration to maintain a satisfactory sexual relationship.
Do not take vardenafil
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Be especially careful with vardenafil
Children and adolescents
Vardenafil should not be used in children or adolescents under 18 years of age.
Other medications and vardenafil
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
Some medications can cause problems, especially the following:
Do not use vardenafil film-coated tablets in combination with another medication for the treatment of erectile dysfunction, including vardenafil orodispersible tablets.
Taking vardenafil with food, beverages, and alcohol
Pregnancy and breastfeeding
Vardenafil should not be used in women.
Driving and using machines
In some people, vardenafil can cause dizziness or affect vision. Do not drive or operate tools or machines if you feel dizzy or have vision problems after taking vardenafil.
Follow the administration instructions of this medication exactly as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is 10 mg.
Take a vardenafil tablet 25 to 60 minutes, approximately, before sexual activity. With sexual stimulation, you can achieve an erection from 25 minutes to 4 or 5 hours after taking vardenafil.
Do not take vardenafil film-coated tabletswith any other formulation of vardenafil.
Do not take vardenafilmore than once a day.
If you think the effect of vardenafil is too strong or too weak, inform your doctor. He or she may suggest changing to another formulation of vardenafil with a different dose based on the effect it has on you.
If you take more Vardenafil than you should
Taking too many vardenafil tablets can cause more side effects and produce intense back pain.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, vardenafil can cause side effects, although not everyone will experience them. Most of these side effects are mild or moderate.
Some patients have experienced sudden vision loss or partial vision loss, distorted, attenuated, or blurred vision, temporarily or permanently, in one or both eyes.
There have also been reports of sudden hearing loss.
There have been reports of sudden death, rapid or altered heartbeats, heart attacks, chest pain, and cerebral circulation problems (including temporary reduction of blood flow to parts of the brain and cerebral hemorrhage) in men taking vardenafil. Most men who experienced these side effects had pre-existing heart problems before taking this medication. It is not possible to determine if these events were directly related to vardenafil.
The possibility of presenting a side effect is described through the following categories:
Very common side effects:may affect more than 1 in 10 people:
Common side effects:may affect up to 1 in 10 people:
Uncommon side effects:may affect up to 1 in 100 people:
Rare side effects:may affect up to 1 in 1,000 people:
Very rare or unknown frequency side effects:may affect less than 1 in 10,000 people or the frequency cannot be estimated from the available data:
Reporting side effects
If you experience any side effect, consult your doctor, even if it is not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after "EXP". The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Levatik
In the tablet core: microcrystalline cellulose, crospovidone, anhydrous colloidal silica, and magnesium stearate.
In the film coating: polyvinyl alcohol, titanium dioxide (E171), talc, macrogol/PEG 3350, methacrylic acid copolymer type C, yellow iron oxide (E172), sodium bicarbonate, and red iron oxide (E172).
Appearance of the product and package contents
Levatik 20 mg are film-coated tablets of light yellow color, round, and marked with "A723" on one side.
Each package contains 2, 4, or 8 tablets.
Not all package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Kern Pharma, S.L.
Venus, 72 - Pol. Ind. Colón II
08228 Terrassa - Barcelona
Spain
Manufacturer
Actavis Ltd.
BLB016 Bulebel Industrial Estate
Zejtun ZTN 3000
Malta
Date of the last revision of this package leaflet: January 2025
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)
http://www.aemps.gob.es